# Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors

> **NCT05862831** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Biotheus Inc.** · enrollment: 285 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** PM1003 Injection

## Key facts

- **NCT ID:** NCT05862831
- **Lead sponsor:** Biotheus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-07
- **Primary completion:** 2025-09-07
- **Final completion:** 2025-11-15
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2023-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862831, "Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05862831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*